Canadian industry is seeking lower costs and improvements

Maintaining a sustainable pricing environment, achieving greater international regulatory convergence, and bolstering the biosimilars sector are among the key priorities for Canada’s off-patent industry, CGPA president Jim Keon told Generics bulletin deputy editor Dave Wallace.